EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Cannabis and Cannabinoids: The Medical Potential of Cannabidiol in Mental and Neurological Disorders

Răzvan Șolea, Eugenia Șerban, Sabina Florina Călugăr-Solea, Endre Mathe iD, Nicoleta Mirela Blebea iD, Gabriel Hancu iD, Georgeta Serban iD

Pharmaceuticals · 06.08.2026 · 19 (8) · 1238

DOI: 10.3390/ph19081238 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 06.08.2026. Verfasst von Răzvan Șolea und 6 weiteren Autor:innen. Beteiligte Einrichtung: Doctoral School of Biomedical Sciences, Faculty of Medicine and Pharmacy, University of Oradea, 1 Decembrie 10, 410073 Oradea, Romania. Die Arbeit nennt 111 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Oradea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Mental and neurological disorders contribute substantially to the global burden of disease, affecting people of all ages and backgrounds. As their prevalence increases with age, their overall impact is expected to grow in the coming decades. Although psychological and pharmacological treatments are available, many patients fail to achieve satisfactory outcomes, underscoring the need for improved therapeutic strategies. Cannabis sativa L. has been used for medicinal purposes for centuries, and cannabidiol (CBD) has attracted increasing attention because of its broad therapeutic potential. Scientific studies indicate that CBD may be beneficial in several mental and neurological disorders.

Methods

A comprehensive literature search was conducted to identify articles investigating the therapeutic potential of CBD and cannabis in selected disorders.

Results

Evidence from preclinical and clinical studies, together with findings from the broader cannabis literature, indicates that CBD may offer therapeutic benefits in a range of conditions, including Alzheimer’s and Parkinson’s disease, anxiety disorders, and epilepsy. Emerging data also support its potential use as an adjunctive therapy for COVID-19. Current research has improved understanding of the neurobiological mechanisms underlying these disorders and the molecular pathways through which CBD may exert its effects. CBD has demonstrated good tolerability, with predominantly mild adverse effects and a favorable safety profile.

Conclusions

Despite promising findings, many available studies are preclinical or involve small patient cohorts, and the mechanisms underlying the therapeutic effects of CBD remain incompletely understood. Further well-designed, randomized, controlled, multicenter trials are needed to establish the efficacy and safety of CBD and support its integration into clinical practice.

Schlagwörter

Stichwörter der Autor:innen

Alzheimer’s diseaseCannabis sativaParkinson’s diseaseanxietycannabidiolepilepsy

Autor:innen und Institutionen

  • Doctoral School of Biomedical Sciences, Faculty of Medicine and Pharmacy, University of Oradea, 1 Decembrie 10, 410073 Oradea, Romania.
  • Department of Environmental Engineering, Faculty of Environmental Protection, University of Oradea, Gen. Magheru 26, 410048 Oradea, Romania.
  • Institute of Nutrition, Faculty of Agriculture and Food Sciences and Environmental Management, University of Debrecen, Boszormenyi 128, HU-4032 Debrecen, Hungary.
  • Department of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, "Ovidius" University from Constanța, Căpitan Aviator Al. Șerbănescu 6, 900470 Constanța, Romania.
  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, "George Emil Palade" University of Medicine, Pharmacy, Science and Technology of Târgu Mures, Gh Marinescu 32, 540142 Târgu Mures, Romania.
  • Department of Pharmaceutical and Therapeutic Chemistry, Faculty of Medicine and Pharmacy, University of Oradea, Nicolae Jiga 29, 410028 Oradea, Romania.

ORCID-Profile: Endre Mathe, Nicoleta Mirela Blebea, Gabriel Hancu, Georgeta Serban

Förderung

  • University of Oradea

Zitieren

APA

Șolea, R., Șerban, E., Călugăr-Solea, S. F., Mathe, E., Blebea, N. M., Hancu, G., & Serban, G. (2026). Cannabis and Cannabinoids: The Medical Potential of Cannabidiol in Mental and Neurological Disorders. Pharmaceuticals, 19(8), 1238. https://doi.org/10.3390/ph19081238

Vancouver

Șolea R, Șerban E, Călugăr-Solea SF, Mathe E, Blebea NM, Hancu G, et al. Cannabis and Cannabinoids: The Medical Potential of Cannabidiol in Mental and Neurological Disorders. Pharmaceuticals. 2026;19(8):1238. doi:10.3390/ph19081238

BibTeX
@article{olea2026,
  author = {Șolea, Răzvan and Șerban, Eugenia and Călugăr-Solea, Sabina Florina and Mathe, Endre and Blebea, Nicoleta Mirela and Hancu, Gabriel and Serban, Georgeta},
  title = {Cannabis and Cannabinoids: The Medical Potential of Cannabidiol in Mental and Neurological Disorders},
  journal = {Pharmaceuticals},
  year = {2026},
  volume = {19},
  number = {8},
  pages = {1238},
  doi = {10.3390/ph19081238}
}
Kostenlos starten →